{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:44:06Z","timestamp":1766090646452,"version":"3.48.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neurol.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:43:21Z","timestamp":1762962201000},"page":"922-928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Presymptomatic late-onset Pompe disease: Optimizing the timing of treatment"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-9515","authenticated-orcid":false,"given":"C.","family":"Gu\u00e9my","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4980","authenticated-orcid":false,"given":"C.","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-0616","authenticated-orcid":false,"given":"E.","family":"Berling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rouyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0026-4727","authenticated-orcid":false,"given":"G.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2025.09.001_bib0110","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1212\/WNL.0000000000207547","article-title":"Characteristics of patients with late-onset Pompe disease in France: insights from the French Pompe Registry in 2022","volume":"101","author":"Lefeuvre","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.09.001_bib0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurol.2025.09.001_bib0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/ijns6020031","article-title":"Newborn screening for Pompe disease","volume":"6","author":"Sawada","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.neurol.2025.09.001_bib0125","first-page":"CD011539","article-title":"Enzyme replacement therapy for infantile-onset Pompe disease","volume":"11","author":"Chen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2025.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.09.001_bib0135","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurol.2025.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.09.001_bib0145","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.09.001_bib0150","doi-asserted-by":"crossref","first-page":"136080","DOI":"10.1016\/j.neulet.2021.136080","article-title":"The future of newborn screening for lysosomal disorders","volume":"760","author":"Wasserstein","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2025.09.001_bib0155","first-page":"5","article-title":"LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population","volume":"87","author":"Musumeci","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.09.001_bib0160","first-page":"98","article-title":"Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state","volume":"9","author":"Matsuoka","year":"2016","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.neurol.2025.09.001_bib0165","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0b013e318228c0ea","article-title":"Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat?","volume":"77","author":"Laloui","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.09.001_bib0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2021.09.001","article-title":"Health care practitioners\u2019 experience-based opinions on providing care after a positive newborn screen for Pompe disease","volume":"134","author":"Davids","year":"2021","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurol.2025.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/jgc4.1421","article-title":"Opinions of adults affected with later-onset lysosomal storage diseases regarding newborn screening: a qualitative study","volume":"30","author":"Lisi","year":"2021","journal-title":"J Genet Couns"},{"key":"10.1016\/j.neurol.2025.09.001_bib0180","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.0b013e318228c15f","article-title":"\u201cI\u2019m fine; I\u2019m just waiting for my disease\u201d: the new and growing class of presymptomatic patients","volume":"77","author":"Kwon","year":"2011","journal-title":"Neurology"},{"year":"2016","series-title":"Protocole National de Diagnostic et de Soins (PNDS) \u201cMaladie de Pompe\u201d","author":"G2M","key":"10.1016\/j.neurol.2025.09.001_bib0185"},{"key":"10.1016\/j.neurol.2025.09.001_bib0190","doi-asserted-by":"crossref","first-page":"e16383","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024","volume":"31","author":"Schoser","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2025.09.001_bib0195","doi-asserted-by":"crossref","first-page":"105277","DOI":"10.1016\/j.nmd.2025.105277","article-title":"Management of presymptomatic juvenile patients with late-onset Pompe disease (LOPD)","volume":"47","author":"Porcino","year":"2025","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurol.2025.09.001_bib0200","doi-asserted-by":"crossref","DOI":"10.1177\/22143602251336661","article-title":"A model to predict the 6-Minute Walk Distance in Pompe disease","author":"El Ka\u00efm","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.neurol.2025.09.001_bib0205","first-page":"58","article-title":"Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy","volume":"3","author":"Gruhn","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.neurol.2025.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/jcsm.12555","article-title":"Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles","volume":"11","author":"Nu\u00f1ez-Peralta","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:39:17Z","timestamp":1766090357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725006083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0035378725006083"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.09.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presymptomatic late-onset Pompe disease: Optimizing the timing of treatment","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}